Autoimmune Disease Therapeutics Market by Drug Class (Anti-Inflammatory, Antihyperglycemics, NSAIDs, Interferons, and Others), Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, , Inflammatory Bowel Disease and Others) and Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Store): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
Autoimmune Disease Therapeutics Market Overview:
The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025.
Immune system disorders occur due to low activity or over activity of the immune system.
An autoimmune disease is a condition in which the immune system mistakenly attacks and damages its own tissues. There are more than 80 different autoimmune diseases exist. Some of the common types of autoimmune diseases are rheumatoid arthritis (RA), psoriasis/psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus (lupus), inflammatory bowel disease, and others.
Autoimmune disease therapeutics are expected to experience significant market growth during the forecast period owing to early diagnosis of the disease, recent launch of advanced therapeutics, and rise in incidence of autoimmune disease. Furthermore, strong presence of late-stage pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others. On the other side higher cost associated with the advanced therapeutics is expected to hamper the market growth.
The global autoimmune disease therapeutics market is segmented based on drug class, indication, sales channel, and region. Based on drug class, the market is classified as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. On the basis of indication, rheumatic disease, type 1 diabetes, multiple sclerosis, rare disease, inflammatory bowel disease, and other indications. According to the sales channel, the market is categorized as hospital pharmacy, drug stores & retail pharmacy, and online store. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Key Benefits for Autoimmune Disease Therapeutics Market:
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Autoimmune Disease Therapeutics Key Market Segments:
By Drug Class
Anti-inflammatory
Antihyperglycemics
NSAIDs
Interferons
Others
By Indication
Rheumatic Disease
Type 1 Diabetes
Multiple Sclerosis
Rare Disease
Inflammatory Bowel Disease
Other Indications
By Sales Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Stores
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
AstraZeneca plc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Johnson & Johnson
Novartis AG
Pfizer Inc.
UCB S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Biogen Inc.
EMD Serono Inc.
GlaxoSmithKline plc
Shire Plc.
Teva Pharmaceutical Industries Ltd.
The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025.
Immune system disorders occur due to low activity or over activity of the immune system.
An autoimmune disease is a condition in which the immune system mistakenly attacks and damages its own tissues. There are more than 80 different autoimmune diseases exist. Some of the common types of autoimmune diseases are rheumatoid arthritis (RA), psoriasis/psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus (lupus), inflammatory bowel disease, and others.
Autoimmune disease therapeutics are expected to experience significant market growth during the forecast period owing to early diagnosis of the disease, recent launch of advanced therapeutics, and rise in incidence of autoimmune disease. Furthermore, strong presence of late-stage pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others. On the other side higher cost associated with the advanced therapeutics is expected to hamper the market growth.
The global autoimmune disease therapeutics market is segmented based on drug class, indication, sales channel, and region. Based on drug class, the market is classified as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. On the basis of indication, rheumatic disease, type 1 diabetes, multiple sclerosis, rare disease, inflammatory bowel disease, and other indications. According to the sales channel, the market is categorized as hospital pharmacy, drug stores & retail pharmacy, and online store. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Key Benefits for Autoimmune Disease Therapeutics Market:
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Autoimmune Disease Therapeutics Key Market Segments:
By Drug Class
Anti-inflammatory
Antihyperglycemics
NSAIDs
Interferons
Others
By Indication
Rheumatic Disease
Type 1 Diabetes
Multiple Sclerosis
Rare Disease
Inflammatory Bowel Disease
Other Indications
By Sales Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Stores
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
AstraZeneca plc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Johnson & Johnson
Novartis AG
Pfizer Inc.
UCB S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Biogen Inc.
EMD Serono Inc.
GlaxoSmithKline plc
Shire Plc.
Teva Pharmaceutical Industries Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Surge in adoption of autoimmune disease therapeutics
3.3.1.2. Increase in incidence of autoimmune disease
3.3.1.3. Wide availibility of adavanced therapeutics
3.3.2. Restraints
3.3.2.1. Higher cost assosiated with advanced autoimmune disease therapeutics
3.3.3. Opportunities
3.3.3.1. Growth opportunities in emerging economies
3.3.3.2. Strong presence of pipeline drugs
3.3.4. Impact Analyses
CHAPTER 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-inflammatory
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Antihyperglycemics
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. NSAIDs
4.4.1 Key market trends, growth factors, and opportunities
4.4.2 Market size and forecast
4.4.3 Market analysis, by country
4.5 Interferons
4.5.1 Key market trends, growth factors, and opportunities
4.5.2 Market size and forecast
4.5.3 Market analysis, by country
4.6 Others
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
CHAPTER 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Rheumatic Disease
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Type 1 Diabetes
5.3.1 Market size and forecast, by region
5.3.2 Market analysis, by country
5.4 Multiple Sclerosis
5.4.1 Market size and forecast, by region
5.4.2 Market analysis, by country
5.5 Inflammatory Bowel Disease
5.5.1 Market size and forecast, by region
5.5.2 Market analysis, by country
5.6 Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacy
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Drug store & retail pharmacy
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online Store
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. autoimmune disease therapeutics market, by drug class
6.2.2.1.2. U.S. autoimmune disease therapeutics market, by indication
6.2.2.1.3. U.S. autoimmune disease therapeutics market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Canada autoimmune disease therapeutics market, by indication
6.2.2.2.3. Canada autoimmune disease therapeutics market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Mexico autoimmune disease therapeutics market, by indication
6.2.2.3.3. Mexico autoimmune disease therapeutics market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.5.4. North America market size and forecast, by indication
6.2.5. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Germany autoimmune disease therapeutics market, by indication
6.3.2.1.3. Germany autoimmune disease therapeutics market, by sales channel
6.3.2.2. France
6.3.2.2.1. France autoimmune disease therapeutics market, by drug class
6.2.2.1.2. France autoimmune disease therapeutics market, by indication
6.3.2.2.3. France autoimmune disease therapeutics market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK autoimmune disease therapeutics market, by drug class
6.2.2.1.2. UK. autoimmune disease therapeutics market, by indication
6.3.2.3.3. UK autoimmune disease therapeutics market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Italy autoimmune disease therapeutics market, by indication
6.3.2.4.3. Italy autoimmune disease therapeutics market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Spain autoimmune disease therapeutics market, by indication
6.3.2.5.3. Spain autoimmune disease therapeutics market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of Europe autoimmune disease therapeutics market, by indication
6.3.2.6.3. Rest of Europe autoimmune disease therapeutics market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.5.4. Europe market size and forecast, by indication
6.3.5. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Japan autoimmune disease therapeutics market, by indication
6.4.2.1.3. Japan autoimmune disease therapeutics market, by sales channel
6.4.2.2. China
6.4.2.2.1. China autoimmune disease therapeutics market, by drug class
6.2.2.1.2. China autoimmune disease therapeutics market, by indication
6.4.2.2.3. China autoimmune disease therapeutics market, by sales channel
6.4.2.3. Australia
6.4.2.3.1. Australia autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Australia autoimmune disease therapeutics market, by indication
6.4.2.3.3. Australia autoimmune disease therapeutics market, by sales channel
6.4.2.4. India
6.4.2.4.1. India autoimmune disease therapeutics market, by drug class
6.2.2.1.2. India autoimmune disease therapeutics market, by indication
6.4.2.4.3. India autoimmune disease therapeutics market, by sales channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea autoimmune disease therapeutics market, by drug class
6.2.2.1.2. South Korea autoimmune disease therapeutics market, by indication
6.4.2.5.3. South Korea autoimmune disease therapeutics market, by sales channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of Asia-Pacific autoimmune disease therapeutics market, by indication
6.4.2.6.3. Rest of Asia-Pacific autoimmune disease therapeutics market, by sales channel
6.4.3. Asia-Pacific market size and forecast, by type
6.5.4. Asia-Pacific market size and forecast, by indication
6.4.5. Asia-Pacific market size and forecast, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Brazil autoimmune disease therapeutics market, by indication
6.5.2.1.3. Brazil autoimmune disease therapeutics market, by sales channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Saudi Arabia autoimmune disease therapeutics market, by indication
6.5.2.2.3. Saudi Arabia autoimmune disease therapeutics market, by sales channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa autoimmune disease therapeutics market, by drug class
6.2.2.1.2. South Africa autoimmune disease therapeutics market, by indication
6.5.2.3.3. South Africa autoimmune disease therapeutics market, by sales channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of LAMEA autoimmune disease therapeutics market, by indication
6.5.2.4.3. Rest of LAMEA autoimmune disease therapeutics market, by sales channel
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by indication
6.5.5. LAMEA market size and forecast, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. AbbVie Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Amgen Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. AstraZeneca plc.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Bristol-Myers Squibb Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. F. Hoffmann-La Roche AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Novartis AG
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Pfizer Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. UCB S.A.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6.Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. Surge in adoption of autoimmune disease therapeutics
3.3.1.2. Increase in incidence of autoimmune disease
3.3.1.3. Wide availibility of adavanced therapeutics
3.3.2. Restraints
3.3.2.1. Higher cost assosiated with advanced autoimmune disease therapeutics
3.3.3. Opportunities
3.3.3.1. Growth opportunities in emerging economies
3.3.3.2. Strong presence of pipeline drugs
3.3.4. Impact Analyses
CHAPTER 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-inflammatory
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Antihyperglycemics
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. NSAIDs
4.4.1 Key market trends, growth factors, and opportunities
4.4.2 Market size and forecast
4.4.3 Market analysis, by country
4.5 Interferons
4.5.1 Key market trends, growth factors, and opportunities
4.5.2 Market size and forecast
4.5.3 Market analysis, by country
4.6 Others
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
CHAPTER 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Rheumatic Disease
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Type 1 Diabetes
5.3.1 Market size and forecast, by region
5.3.2 Market analysis, by country
5.4 Multiple Sclerosis
5.4.1 Market size and forecast, by region
5.4.2 Market analysis, by country
5.5 Inflammatory Bowel Disease
5.5.1 Market size and forecast, by region
5.5.2 Market analysis, by country
5.6 Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacy
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Drug store & retail pharmacy
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online Store
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. autoimmune disease therapeutics market, by drug class
6.2.2.1.2. U.S. autoimmune disease therapeutics market, by indication
6.2.2.1.3. U.S. autoimmune disease therapeutics market, by sales channel
6.2.2.2. Canada
6.2.2.2.1. Canada autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Canada autoimmune disease therapeutics market, by indication
6.2.2.2.3. Canada autoimmune disease therapeutics market, by sales channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Mexico autoimmune disease therapeutics market, by indication
6.2.2.3.3. Mexico autoimmune disease therapeutics market, by sales channel
6.2.3. North America market size and forecast, by drug class
6.5.4. North America market size and forecast, by indication
6.2.5. North America market size and forecast, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Germany autoimmune disease therapeutics market, by indication
6.3.2.1.3. Germany autoimmune disease therapeutics market, by sales channel
6.3.2.2. France
6.3.2.2.1. France autoimmune disease therapeutics market, by drug class
6.2.2.1.2. France autoimmune disease therapeutics market, by indication
6.3.2.2.3. France autoimmune disease therapeutics market, by sales channel
6.3.2.3. UK
6.3.2.3.1. UK autoimmune disease therapeutics market, by drug class
6.2.2.1.2. UK. autoimmune disease therapeutics market, by indication
6.3.2.3.3. UK autoimmune disease therapeutics market, by sales channel
6.3.2.4. Italy
6.3.2.4.1. Italy autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Italy autoimmune disease therapeutics market, by indication
6.3.2.4.3. Italy autoimmune disease therapeutics market, by sales channel
6.3.2.5. Spain
6.3.2.5.1. Spain autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Spain autoimmune disease therapeutics market, by indication
6.3.2.5.3. Spain autoimmune disease therapeutics market, by sales channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of Europe autoimmune disease therapeutics market, by indication
6.3.2.6.3. Rest of Europe autoimmune disease therapeutics market, by sales channel
6.3.3. Europe market size and forecast, by drug class
6.5.4. Europe market size and forecast, by indication
6.3.5. Europe market size and forecast, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Japan autoimmune disease therapeutics market, by indication
6.4.2.1.3. Japan autoimmune disease therapeutics market, by sales channel
6.4.2.2. China
6.4.2.2.1. China autoimmune disease therapeutics market, by drug class
6.2.2.1.2. China autoimmune disease therapeutics market, by indication
6.4.2.2.3. China autoimmune disease therapeutics market, by sales channel
6.4.2.3. Australia
6.4.2.3.1. Australia autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Australia autoimmune disease therapeutics market, by indication
6.4.2.3.3. Australia autoimmune disease therapeutics market, by sales channel
6.4.2.4. India
6.4.2.4.1. India autoimmune disease therapeutics market, by drug class
6.2.2.1.2. India autoimmune disease therapeutics market, by indication
6.4.2.4.3. India autoimmune disease therapeutics market, by sales channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea autoimmune disease therapeutics market, by drug class
6.2.2.1.2. South Korea autoimmune disease therapeutics market, by indication
6.4.2.5.3. South Korea autoimmune disease therapeutics market, by sales channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of Asia-Pacific autoimmune disease therapeutics market, by indication
6.4.2.6.3. Rest of Asia-Pacific autoimmune disease therapeutics market, by sales channel
6.4.3. Asia-Pacific market size and forecast, by type
6.5.4. Asia-Pacific market size and forecast, by indication
6.4.5. Asia-Pacific market size and forecast, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Brazil autoimmune disease therapeutics market, by indication
6.5.2.1.3. Brazil autoimmune disease therapeutics market, by sales channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Saudi Arabia autoimmune disease therapeutics market, by indication
6.5.2.2.3. Saudi Arabia autoimmune disease therapeutics market, by sales channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa autoimmune disease therapeutics market, by drug class
6.2.2.1.2. South Africa autoimmune disease therapeutics market, by indication
6.5.2.3.3. South Africa autoimmune disease therapeutics market, by sales channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA autoimmune disease therapeutics market, by drug class
6.2.2.1.2. Rest of LAMEA autoimmune disease therapeutics market, by indication
6.5.2.4.3. Rest of LAMEA autoimmune disease therapeutics market, by sales channel
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by indication
6.5.5. LAMEA market size and forecast, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. AbbVie Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Amgen Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. AstraZeneca plc.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Bristol-Myers Squibb Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product Portfolio
7.5.5. Business performance
7.6. F. Hoffmann-La Roche AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Novartis AG
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Pfizer Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. UCB S.A.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6.Key strategic moves and developments
